Concepedia
Statistics
Publications
28
Citations
1.5K
H-Index
16
Active since
2007
Affiliations
Columbia University Irving Medical Center(Current)
Memorial Sloan Kettering Cancer Center
Columbia University
Dana-Farber Cancer Institute
BC Cancer Agency
Ahmed Sawas is an author at Columbia University Irving Medical Center specializing in medicine, oncology, and immunotherapy.
Publications per year
2007–2024
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas et al. · Blood · 2018 · 253 citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin et al. · Clinical Cancer Research · 2021 · 196 citations · Full text
Medicine, Hematology, Pharmacology +17
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue et al. · Blood · 2017 · 134 citations · Full text
Life Sciences, Immunology, Oncology +8
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
Owen A. O’Connor, Lorenzo Falchi, Jennifer Kimberly Lue et al. · Blood · 2019 · 128 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +4
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas et al. · The Lancet Oncology · 2017 · 118 citations · Full text
Medicine, Oncology, Pharmacology +16
1–5 of 28